Modern approaches to treatment of osteoarthritis: the role of injectable slow-acting symptom-modifiing preparations


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

The article discusses the causes of pain in osteoarthritis (OA), the role of inflammation in the pathogenesis of the disease, and the limitation of the use of nonsteroidal anti-inflammatory drugs (NSAIDs). The current international recommendations 2014 and 2016, according to which treatment of OA is recommended to start with slow-acting symptom-modifying drugs (SYSADOA - Symptomatic Slow-Acting Drugs in Osteoarthritis), are presented. Data on analgesic and anti-inflammatory effects of chondroitin sulfate (ChS), and its safety are given. It is shown that it is possible to achieve a more rapid effect when using the injectable dosage form of ChS. Data on the mechanism of action, safety and efficacy of hyaluronic acid preparations are discussed.

Full Text

Restricted Access

About the authors

N. V Chichasova

FSAEI HE I.M. Sechenov First Moscow State Medical University MHRF (Sechenov University)

Email: kafedrarheum@yandex.ru
MD, Prof. at the Department of Rheumatology

References

  1. Hochberg M.C. Osteoarthritis year 2012 in review: clinical. Osteoarthritis Cartilage 2012;20:1465-69.
  2. Lane N.E., Shidara K., Wise B.L. Osteoarthritis year in review 2016: clinical. Osteoarthritis Cartilage. 2017;25:209-15.
  3. Knoop J., van der Leeden M., Thorstensson C.A., Roorda L.D., Lems W.F., Knol D.L., Steultjens M.P.M., Dekker J. Identification of phenotypes with different clinical outcomes in knee osteoarthritis: data from the osteoarthritis Initiative. Arthr. Care Res. 2011;63:1535-42.
  4. Brooks P.M. Impact of osteoarthritis on individuals and society: how much disability? Social consequences and health economic implications. Curr. Opin. Rheum. 2002; 14:573-77.
  5. Kadam U.T., Jordan K., Craft P.R. Clinical comorbidity in patients with osteoarthritis: a case-control study of general practice consulters in England and Walls. Ann. Rheum. Dis. 2004;63:408-14.
  6. Simoes D., Araujo F.A., Severo M., Nonjardino Cruz I., Carmona L., Lugas R. Patterns and consequences of multimobidity in general population: there is nonchronic disease management without rheumatic disease management. Arthr. Care Res. 2017;69:12-20.
  7. Matiessen A., Conaghan P. Synovitis in osteoarthritis: current understanding with therapeutic implications. Arthr. Res. Ther. 2017;19:18.
  8. Bakhriansyah M., Souverein P.C., de Boer A., Klungel O.H. Gastrointestinal toxicity among patients taking selective COX-2 inhibitors or conventional NSAIDs, alone or combined with proton pump inhibitors: a case-control study. Pharmacoepidem. Drug. Safety. 2017;26: 1141-48.
  9. Breivik H. NSAIDs relieve osteoarthritis pain? But cardiovascular safety in question even for diclofenac, ibuprofen, naproxen, and celecoxib: what are the alternatives? Scand. J. Pain. 2017;16:148-49.
  10. Fanelli A., Daniela Ghisi D., Pierangelo Aprile L., Lapi F. Cardiovascular and cerebrovascular risk with nonsteroidal anti-inflammatory drugs and cyclooxygenase 2 inhibitors: latest evidence and clinical implications. Ther. Adv. Drug Saf. 2017;8:73-82.
  11. Балабанова Р.М., Запрягаева М.Е. Роль нестероидных противовоспалительных препаратов в комплексной терапии остеоартроза. Consilium medicum. 2005;7(12).
  12. Bruyere O., Cooper C.C., Pelletier J.-P, et.al. An algorithm recommendation for the management of knee osteoarthritis in Europe and internationally: A report from a task force of the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO). Sem. Arthr. Rheum. 2014;44:252-63.
  13. Bruyere O., Cooper C., Pelletier J.-P., et.al. A consensus statement on the European Society for clinical and economic aspects of osteoporosis and osteoarthritis (ESCEO) algorithm for the management of knee osteoarthritis - from evidence-based medicine to the real-life setting. Sem. Arthr. Reum. 2016;45:1-11.
  14. Насонов Е.Л., Яхно Н.Н., Каратеев А.Е., Алексеева Л.И., Баринов А.Н., Барулин А.Е., Давыдов О.С., Данилов А.Б., Журавлева М.В., Заводовский Б.В., Копенкин С.С., Кукушкин М.Л., Парфенов В.А., Страхов М.А., Тюрин В.П., Чичасова Н.В., Чорбинская С.А. Общие принципы лечения скелетно-мышечной боли: междисциплинарный консенсус. Научно-практическая ревматология. 2016; 54:247-65.
  15. Reachenbach S., Sterchl R., Scherer M, Trelle S., Burgi E., Burgi U., Dieppe P.A. Meta-analysis: Chondroitin for osteoarthritis of the knee and hip. Ann Int Med 2007;146:580-90.
  16. Mazieres B., Combe B., Phan Van V., et.al. Chondroitin sulfate in osteoarthritis of the knee: a prospective, double blind, placebo controlled multicenter clinical study. J. Rheum. 2001;28:173-81.
  17. Pelletier J.P., Raynauld J.P., Beaulieu A.D., Bessette L., Morin F., de Brum-Fernandes A.J., Delorme P., Dorais M., Paiement P., Abram F., Martel-Pelletier J. Chondroitin sulfate efficacy versus celecoxib on knee osteoarthritis structural changes using magnetic resonance imaging: a 2-year multicenter exploratory study. Arthr. Res. Ther. 2016;18:256.
  18. Morreale P., Manopulo R., Galati M. Comparison of the antiinflammatory efficacy of chondroitinsulfate and diclofenac sodium in patients with knee osteoarthritis. J. Rheum. 1996;23: 1385-91.
  19. Uebelchart D., Knussen O., Theiler R. Ability of oral chondroitinsulfate in painful knee osteoarthritis: a double-blind, placebo-controlled, multicenter 6 month trial. Osteoarthritis Cartilage 1999;7(Suppl. A):Abstr.144.
  20. Mazieres B., Combe B., Phan van A., Tondut J., Grynfeltt M. Chondroitin sulphate in osteoarthritis of the knee: a prospective, double blind, placebo-controlled multicenter clinical study. J. Rheum. 2001;8:173-81.
  21. Lebb B.F., Schweitzer H., Montag K., Smolen J.S. A meta-analysis of chondroitin-sulfate in the treatment of osteoarthritis. J. Rheum. 2000;27:205-11.
  22. Bana G., Jamard B., Verrouil E., Mazieres B. Chondroitin sulfate in the management of hip and knee OA: an overview. Adv. Pharmacol. 2006;53:507-22.
  23. McAlindon T.E., LaValley M.P., Gulin J.P., Felson D.T. Glucosamine and chondroitin for treatment of osteoarthritis: a systematic quality assessment and meta-analysis. JAMA. 2000;283: 1469-75.
  24. Jordan K.M., Arden N.K., Doherty M., Bannwarth B., Bijlsma J.W.J., Dieppe P., Gunther K., Hauselmann H., Herrero-Beaumont G., Kaklamanis P., Lohmander S., Leeb B., Lequesne M., Mazieres B., Martin-Mola E., Pavelka K., Pendleton A., Punzi L., Serni U., Swoboda B., Verbruggen G., Zimmerman-Gorska I., Dougados M. EULAR Recommendation 2003: an evidence based approach to the management of knee osteoarthritis: Report of a Task Force of the Standing Committee for International Clinical Studies Including Therapeutic Trials (ESCISIT). Ann. Rheum. Dis. 2003;62:1145-55.
  25. Hochberg M., Chevalier X., Henrotin Y., Hunter D.J., Uebelhart D. Symptom and structure modification in osteoarthritis with pharmaceutical-grade chondroitin sulfate: what's the evidence? Curr. Med. Res. Opin. 2013;29:259-67.
  26. Hochberg M.C., Zhan M., Langenberg P. The rate of decline of joint space width in patients with osteoarthritis of the knee: a systematic review and meta-analysis of randomized placebocontrolled trials of chondroitin sulfate. Curr. Med. Res. Opin. 2008;24:3029-35.
  27. Ronca F., Palmieri L., Panicucci P., Ronca G. Antiinflammatory activity of chondroitin sulfate. Osteoarthritis Cartilage.1998;6:14-21.
  28. Шостак Н.А., Правдюк Н.Г., Клименко А.А., Кондрашов А.А., Шеменкова В.С., Егорова В.А. Остеоартроз - новые возможности симптоммодифицирующей терапии замедленного действия. Клиницист. 2013;3-4:93-7.
  29. Haskall V.C., Laurent T.C. Hyaluronan structure and physical properties. 1997. Available at: // www/glycoforum.gr.jp.scince/hyaluronan/ HAO1/HAO1E.html.
  30. Gahl L.B., Dahl I.M.S., Engstrom A., Granath K. Concentration and molecular weight of sodium hyaluronate in synovial fluid from patients with rheumatoid arthritis and other arthropathies. Ann. Rheum. Dis 1985;44:817-22.
  31. Balazs E.A., Denlinger J.L. Viscosupplemetation: a new concept in the treatment of osteoarthritis. J. Rheumatol 1993;Suppl. 39:3-9.
  32. Goldenberg V.M., Bucwalter J.A. Hyaluronans in the treatment of osteoarthritis of the knee: evidence for disease-modifying activity. Osteoarthritis and Cartilage. 2005;13:216-24.
  33. Uebelhart D., Williams J.M. Effect of hyaluronic acid on cartilage degradation. Curr. Opin. Rheum. 1999;11:427-35.
  34. Ghosh P., Guidolin D. Potential mechanism of action of intra-articular hyaluronan therapy in osteoarthritis: are the effect molecular weights dependent? Semin. Arthr. Rheum. 2002; 32:10-37.
  35. Punzi L. The complexity of the mechanisms of action of hyaluronan in joint diseases. Clin. Exp. Rheum. 2001;19:242-46.
  36. Julovi S.M., Yasuda T., Shimizu M., Hiramitsu T., Nakamura T. Inhibition of interleukin-1beta-stimulated production of matrix metalloproteases by hyaluronan via CD44 in human articular cartilage. Arthr. Rheum. 2004;50:516-25.
  37. Tetlow L.C., Adlam D.J., Wooley D.E. Matrix metalloproteinase and proinflammatory cytokine production by chondrocytes of human osteoarthritic cartilage: association with degenerative changes. Arthr. Rheum. 2001;44:585-94.
  38. Takahashi K., Hashimoto S., Kubo T., Hiramitsu T. Effect of hyaluronan on chondrocyte apoptosis and nitric oxide production in experimentally induced osteoarthritis. J. Rheum. 2000;27:1713-20.
  39. Dougados M., Nguyen M., Listrat V., Amor B. High molecular weight sodium hyaluronate (hyalectin) in osteoarthritis of the knee: a 1 year placebo-controlled trial. Osteoarthr. Cartilage. 1993;1:97-103.
  40. Smith M.M., Ghosh P. The synthesis of hyaluronic acid by human synovial fibroblasts is influenced by the nature of hyaluronate in the extracellular environment. Rheum. Int. 1987;7:113-22.
  41. Gigis I, Fotiadis E., Nenopulos A., Tsitas K., Hatzokos I. Comparison of two different weight intra-articular injections of hyaluronic acid for the treatment of knee osteoarthritis. Hippocratia. 2016;1:26-31.
  42. Kukuchi T., Yamada H., Shimmer M. Effect of high molecular weight hyaluronan on cartilage degradation in a rabbit model of osteoarthritis. Osteoarthritis and cartilage 1996;4:99-102.
  43. Petrella R.J., Wakeford C. Pain relief and improved physical function in knee osteoarthritis patients receiving ongoing hylan G-F 20, a high-moleculare-weight hyaluronan, versus other treatment options: Data from a large real-word longitudinal cohort in Canada. Drug Des. Devel. Ther. 2015;9:5633-40.
  44. Karatosun V., Unver B., Gocen Z., Sen A. Comparison of two hyaluronan drugs in patients with advanced osteoarthritis of the knee. A prospective, randomized, double-blind study with long-term follow-up. Clin. Exp. Rheum. 2005;23:213-18.
  45. Allard S., O'Regan M. The role of elastoviscosity in the efficacy of viscosupplementation for osteoarthritis of the knee: a comparison of hylan G-F 20 and a lower-molecular-weight hyaluronan. Clin. Ther. 2000;22:792-95.
  46. Prichard C.H., Sripada P., Bankes P., et.al. A retrospective comparison on the efficacy and tolerability of sodium hyaluronate and hylan G-F 20 in the treatment of osteoarthritis of the knee. J. Musculoskelet. Res. 2002;6:197-205.
  47. Jumi P., Reichembach S., Trelle S. Swiss Viscosupplementation Trial Group. Efficacy and safety of intraarticular hylan or hyaluronic acids for osteoarthritis of the knee: a randomized controlled trial. Arthr. Rheum. 2007; 56:3610-19.
  48. Yoshiola M., Shimizu C., Harwood F.L., et.al. The effects of hyaluronan during the development of osteoarthritis. Osteoarthritis and cartilage. 1997;5:251-60.
  49. Wang C.T., Lin J., Chang C.J., Lin Y.T., Hou S.M. Therapeutic effects of hyaluronic acid on osteoarthritis of the knee: A meta-analysis of randomized controlled trials. J. Bone Joint Surg. Am. 2004;86-A:538-45.
  50. Arrich, Piribauer F., Mad P., Schmid D., Klaushofer K., Mullner M. Intra-articular hyaluronic acid for the treatment of osteaoarthritis of the knee: Systematic review and meta-analysis. CMAJ. 2005;172:1039-43.
  51. Bellamy N., Cambell J., Robinson V., Gee T., Bourne R., Wells G. Viscosocupplementation for the treatment of osteoarthritis of the knee. Cochrane Database Syst. Rev. 2006:CD005321.
  52. Medina J.M., Thomas A., Denegar C.R. Knee osteoarthritis: Should your patient opt for hyaluronic acid injection? J. Fam. Pract. 2006;55:669-75.
  53. Rutjes A.W., Juni P., daCosta B.R.,Trelle S.,Nuesch E., Reichenbach S. Viscosocupplementation for osteoarthritis of the knee: A systematic review and meta-analysis. Ann. Intern. Med. 2012;57:180-91.
  54. Miller L.E., Block J.E. US-approved intra-articular hyaluronic acid injections are safety and effective in patients with knee osteoarthritis: Systematic review and meta-analysis of randomized, saline-controlled trials. Clin. Med. Insights Arthr. Musculoscelet Disord. 2013;6:57-63.
  55. Bannuru R.R., Schmid C.H., Kent D.M., Vaysbrot E.E., Wong J.B., McAlindon T.E. Comparative effectiveness of pharmacological interventions for knee osteoarthritis: A systematic review and network meta-analysis. Ann. Intern. Med. 2015;162:46-54.
  56. Piccirilli E., Oliva F., Murè M.A., Mahmoud A., Foti C., Tarantino U., Maffulli N. Viscosupplementation with intra-articular hyaluronic acid for hip disorders. A systematic review and meta-analysis. Muscules Ligaments Tendons. J. 2016;6:293-99.
  57. Concoff A., Niazi F., Shaw P., Rosen J. Intra-articular hyaluronic acid delay to total knee arthroplasty by number of injection courses receivedл analysis of an administrative database. Arthr. Rheum. 2017;Abstr. Suppl. ACR/APHR Ann. Meeting Novenber 3-8 2017, Sun Diego, USA, abstr. 1198.
  58. Долгова Е.А., Заигрова Н.К., Ракита Д.Р Сравнительная оценка эффективности препаратов хондроитин сульфата и гиалуроновой кислоты при остеоартрозе коленных суставов. Российский медико-биологический вестник им. Акад. И.П. Павлова, №1, 2012, с. 97-102.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies